Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.

ABSTRACT:

Aim

To assess cardiovascular, glycaemic, weight and safety outcomes of long-term treatment with dulaglutide 1.5 mg compared with placebo in patients with a baseline HbA1c of less than 7% versus 7% or higher.

Materials and methods

Intention-to-treat analyses were performed on REWIND participants with a baseline HbA1c measurement, using Cox proportional hazards regression and mixed model for repeated measures. Subgroup analyses with factors for baseline HbA1c categories and their interaction with treatment group, as well as analyses within the HbA1c subgroups, were conducted. Additionally, sensitivity analyses were performed for baseline HbA1c subgroups of 6.5% or less and more than 6.5%.

Results

Of the 9876 eligible participants, 3921 and 5955 had a baseline HbA1c of l

SUBMITTER: Franek E 

PROVIDER: S-EPMC9543284 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature